Radioimmunoimaging with mixed monoclonal antibodies of nude mice bearing human lung adenocarcinoma xenografts

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 9, 2012, Pages 4255-4261

  Duan, Dong ^a   Li, Shao Lin ^b   Zhu, Yu Quan ^a   Zhang, Tao ^a   Lei, Cheng Ming ^a   Cheng, Xiang Hua ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

CD44; EGFR; Molecular imaging; Monoclonal antibody; Radioimmunoimaging

Indexed keywords

EID: 84874009152     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.9.4255     Document Type: Article

References (31)

1. 99mTc-labelled antibodies. Hepatogastroenterology, 58, 347-51.
2. Bellomi M, Rampinelli C, Funicelli L, et al (2006). Screening for lung cancer. Cancer Imaging, 6, 9-12.
3. Boswell CA, Brechbiel MW (2007). Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. Nucl Med Biol, 34, 757-78.
4. Cichy J, Kulig P, Puré E (2005). Regulation of the release and function of tumor cell-derived soluble CD44. Biochim Biophys Acta, 1745, 59-64.
5. Egri G, Takáts A (2005). The immunodiagnosis of lung cancer with monoclonal antibodies. Med Sci Monit, 11, 296-300.
6. Eren B, Sar M, Oz B (2008). MMP-2, TIMP-2 and CD44v6 Expression in Non-small-cell Lung Carcinomas. Ann Acad Med Singapore, 37, 32-9.
7. Fritzberg AR, Abrams PG, Beaumier PL, et al (1988). Specific and stable labeling of antibodies with technetium with a diamide dithiolate chelating agent. Proc Natl Acad Sci USA, 85, 4025-9.
8. Fukui T, Mitsudomi T (2008). Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers. Gen Thorac Cardiovasc Surg, 56, 97-103.
9. Gao SP, Mark KG, Leslie K, et al (2007). Mutations in the EGFR kinase domain me-diates STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest, 117, 3846-56.
10. Gmeiner Stopar T, Fettich J, Zver S, et al (2008). 99mTc-labelled rituximab, a new non-Hodgkin's lymphoma imaging agent: first clinical experience. Nucl Med Commun, 29, 1059-65.
11. Goldenberg DM, Chatal JF, Barbet J, et al (2007). Cancer imaging and therapy with bispecific antibody pretargeting. Update Cancer Ther, 2, 19-31.
12. Goldenberg DM, Sharkey RM, Paganelli G, et al (2006). Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol, 24, 823-34.
13. Granville CA, Dennis PA (2005). An overview of lung cancer genomics and proteomics. Am J Respir Cell Mol Biol, 32, 169-76.
14. Greenlee RT, M urray T, Bolden S, et al (2000). Cancer statistics 2000. CA Cancer J Clin, 50, 7-33.
15. Hay RV, Cao B, Skinner RS, et al (2002). Radioimmunoscintigraphy of tumors autocrine for human met and hepatocyte growth factor/scatter factor. Mol Imaging, 1, 56-62.
16. Hirsch FR, Dziadziuszko R, Thatcher N, et al (2008.) Epidermal growth factor receptor immunohistochemistry;comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer. Cancer, 112, 1114-21.
17. Ikeda K, Nomori H, Mori T, et al (2008). Novel germline mutation: EGFR V843I in patient with multiple lung adenocarcinomas and family members with lung cancer. Ann Thorac Surg, 85, 1430-2.
18. Jin Y, Li JP, Tang LY, et al (2011). Protein expression and significance of VEGF, EGFR and MMP-9 in non-small cell lung carcinomas. Asian Pac J Cancer Prev, 12, 1473-6.
19. Kwa HB, Wesseling J, Verhoeven AH, et al (1996). Immunoscintigraphy of small-cell lung cancer xenografts with anti neural cell adhesion molecule monoclonal antibody, 123C3: improvement of tumour uptake by internalisation. Br J Cancer, 73, 439-46.
20. Lopez AD (1998). Counting the dead in China: measuring tobacco's impact in the developing world. BMJ, 317, 1399-400.
21. Machac J, Krynyckyi B, Kim C (2002). Peptide and antibody imaging in lung cancer. Semin Nucl Med, 32, 276-92.
22. Malle D, Valeri RM, Phatiou C, et al (2005). Significance of immunocytochemical expression of E-cadherin, N-cadherin and CD44 in serous effusions using liquid-based cytology. Acta Cytol, 49, 11-6.
23. Neal RD, Allgar VL, Ali N, et al (2007). Stage, survival and delays in lung, colorectal, prostate and ovarian cancer: comparison between diagnostic routes. Br J Gen Pract, 57, 212-9.
24. Petronzelli F, Pelliccia A, Anastasi AM, et al (2005). Improved tumor targeting by combined use of two antitenascin antibodies. Clin Cancer Res, 11, 7137-45.
25. Ren XL, Wang J, Jin BQ, et al (2001). Lung cancer radioimmunoimaging using 99Tcm-labeled anti-epidermal growth factor recepter monoclonal antibody in nude mice. Chin J Nucl Med, 21, 28-9.
26. Rom WN, Hay JG, Lee TC, et al (2000). Molecular and genetic aspects of lung cancer. Am J Respir Crit Care Med, 16, 1355-67.
27. Rusch V, Macapinlac H, Heelan R, et al (1993). NR-LU monoclonal antibody scanning. A helpful new adjunct to computed tomography in evaluating non-small-cell lung cancer. J Thorac Cardiovasc Surg, 106, 200-4.
28. Sartori G, Bettelli S, Schirosi L, et al (2007). Microsatellite and EGFR, HER2 and K-RAS analyses in sclerosing hemangioma of the lung. Am J Surg Pathol, 31, 1512-20.
29. Shi L, Wu M, Chen H (1997). Radioimmunologic targeting and therapy with antihuman primary hepatic cancer monoclonal antibodies (Hepama I) in patients. Zhonghua Zhong Liu Za Zhi, 19, 146-9.
30. Smith-Jones PM, Pandit-Taskar N, Cao W, et al (2008). Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb. Nucl Med Biol, 35, 343-51.
31. Tachfouti N, Belkacemi Y, Raherison C, et al (2012). First data on direct costs of lung cancer management in Morocco. Asian Pac J Cancer Prev, 35, 1813-5.